Free Trial
→ Shots officially fired… (From Brownstone Research) (Ad)tc pixel Free NUVL Stock Alerts

Nuvalent (NUVL) Financials

Nuvalent logo
$93.39 +2.50 (+2.75%)
Closing price 10/24/2025 04:00 PM Eastern
Extended Trading
$93.40 +0.01 (+0.01%)
As of 10/24/2025 05:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Nuvalent

Annual Income Statements for Nuvalent

This table shows Nuvalent's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -15 -46 -82 -126 -261
Consolidated Net Income / (Loss)		 -15 -46 -82 -126 -261
Net Income / (Loss) Continuing Operations		 -15 -46 -82 -126 -261
Total Pre-Tax Income 		-15 -46 -82 -126 -260
Total Operating Income		 -17 -46 -86 -149 -280
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 17 46 86 149 280
Selling, General & Admin Expense		 1.50 10 22 36 63
Research & Development Expense		 15 36 64 113 218
Total Other Income / (Expense), net		 2.35 -0.52 4.25 23 20
Income Tax Expense		 - - 0.00 0.00 0.76
Basic Earnings per Share		 ($5.08) ($2.13) ($1.65) ($2.17) ($3.93)
Weighted Average Basic Shares Outstanding		 2.87M 21.78M 49.67M 58.22M 66.41M
Diluted Earnings per Share		 ($5.08) ($2.13) ($1.65) ($2.17) ($3.93)
Weighted Average Diluted Shares Outstanding		 2.87M 21.78M 49.67M 58.22M 66.41M
Weighted Average Basic & Diluted Shares Outstanding		 - 96.63M 56.70M 64.07M 71.60M

Quarterly Income Statements for Nuvalent

This table shows Nuvalent's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -20 -26 -25 -30 -33 -37 -44 -57 -81 -77 -85
Consolidated Net Income / (Loss)		 -20 -26 -25 -29 -34 -38 -44 -57 -84 -75 -85
Net Income / (Loss) Continuing Operations		 -20 -26 -25 -29 -34 -38 -44 -57 -84 -75 -85
Total Pre-Tax Income 		-20 -26 -25 -29 -34 -38 -44 -57 -84 -75 -84
Total Operating Income		 -20 -29 -30 -34 -39 -46 -53 -65 -76 -86 -95
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 20 29 30 34 39 46 53 65 76 86 95
Selling, General & Admin Expense		 5.76 6.44 8.09 8.14 9.17 11 14 16 16 17 20
Research & Development Expense		 15 23 22 26 30 36 39 49 61 69 74
Total Other Income / (Expense), net		 0.67 3.18 5.02 4.97 5.14 8.15 8.49 8.15 -7.97 12 10
Income Tax Expense		 - - 0.00 0.00 0.00 - 0.38 0.17 0.04 0.17 0.16
Basic Earnings per Share		 ($0.41) ($0.50) ($0.44) ($0.51) ($0.59) ($0.63) ($0.69) ($0.88) ($1.28) ($1.08) ($1.18)
Weighted Average Basic Shares Outstanding		 48.41M 49.67M 56.70M 56.87M 57.09M 58.22M 64.15M 64.61M 65.68M 66.41M 71.61M
Diluted Earnings per Share		 ($0.41) ($0.50) ($0.44) ($0.51) ($0.59) ($0.63) ($0.69) ($0.88) ($1.28) ($1.08) ($1.18)
Weighted Average Diluted Shares Outstanding		 48.41M 49.67M 56.70M 56.87M 57.09M 58.22M 64.15M 64.61M 65.68M 66.41M 71.61M
Weighted Average Basic & Diluted Shares Outstanding		 56.44M 56.70M 56.82M 57.02M 62.63M 64.07M 64.56M 64.80M 71.05M 71.60M 71.81M

Annual Cash Flow Statements for Nuvalent

This table details how cash moves in and out of Nuvalent's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 7.32 58 173 94 -190
Net Cash From Operating Activities		 -15 -40 -65 -100 -185
Net Cash From Continuing Operating Activities		 -15 -40 -65 -100 -185
Net Income / (Loss) Continuing Operations		 -15 -46 -82 -126 -261
Consolidated Net Income / (Loss)		 -15 -46 -82 -126 -261
Amortization Expense		 0.00 0.22 -0.37 -10 -15
Non-Cash Adjustments To Reconcile Net Income		 -1.66 4.18 10 26 79
Changes in Operating Assets and Liabilities, net		 1.27 1.94 6.93 11 12
Net Cash From Investing Activities		 0.00 -220 -11 -144 -574
Net Cash From Continuing Investing Activities		 0.00 -220 -11 -144 -574
Purchase of Investments		 0.00 -221 -213 -459 -1,025
Sale and/or Maturity of Investments		 0.00 1.02 202 316 451
Net Cash From Financing Activities		 22 318 249 337 569
Net Cash From Continuing Financing Activities		 22 318 249 337 569
Repayment of Debt		 -0.25 0.28 -0.91 0.00 -0.62
Repurchase of Common Equity		 0.00 -3.02 -0.64 -0.86 -0.48
Issuance of Preferred Equity		 23 145 0.00 0.00 0.00
Issuance of Common Equity		 0.00 177 250 338 570
Other Financing Activities, net		 0.02 -0.96 0.00 -0.78 0.00

Quarterly Cash Flow Statements for Nuvalent

This table details how cash moves in and out of Nuvalent's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Change in Cash & Equivalents		 0.40 165 -152 -19 18 247 -237 -21 292 -224 -25
Net Cash From Operating Activities		 -18 -18 -24 -22 -23 -30 -36 -41 -46 -62 -55
Net Cash From Continuing Operating Activities		 -18 -18 -24 -22 -23 -30 -36 -41 -46 -62 -55
Net Income / (Loss) Continuing Operations		 -20 -26 -25 -29 -34 -38 -44 -57 -84 -75 -85
Consolidated Net Income / (Loss)		 -20 -26 -25 -29 -34 -38 -44 -57 -84 -75 -85
Amortization Expense		 -0.00 -0.83 -2.54 -2.85 -2.63 -2.09 -3.38 -3.43 -2.92 -4.93 -4.28
Non-Cash Adjustments To Reconcile Net Income		 2.65 3.02 5.37 5.85 6.85 7.49 14 15 32 17 22
Changes in Operating Assets and Liabilities, net		 -1.11 6.16 -2.06 3.96 6.44 2.69 -2.08 4.31 9.39 0.22 12
Net Cash From Investing Activities		 18 -65 -127 1.59 38 -56 -207 16 -213 -170 25
Net Cash From Continuing Investing Activities		 18 -65 -127 1.59 38 -56 -207 16 -213 -170 25
Purchase of Investments		 -20 -163 -188 -82 -23 -167 -283 -89 -341 -312 -277
Sale and/or Maturity of Investments		 37 97 61 83 62 110 76 105 128 142 303
Net Cash From Financing Activities		 1.01 249 -0.02 1.30 2.14 333 5.99 4.14 550 8.49 4.55
Net Cash From Continuing Financing Activities		 1.01 249 -0.02 1.30 2.14 333 5.99 4.14 550 8.49 4.55
Repurchase of Common Equity		 - -0.64 -0.09 - - -0.77 0.00 - -0.19 -0.30 -0.01
Issuance of Common Equity		 - 250 0.62 1.66 1.39 335 6.45 4.29 550 8.79 4.55
Other Financing Activities, net		 0.39 -0.61 - - - - - - - - 0.00

Annual Balance Sheets for Nuvalent

This table presents Nuvalent's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 11 294 482 732 1,142
Total Current Assets		 11 291 478 726 1,132
Cash & Equivalents		 10 69 242 335 146
Short-Term Investments		 0.00 220 230 385 973
Prepaid Expenses		 0.31 2.52 5.83 6.58 14
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 0.00 3.20 4.47 5.90 9.30
Total Liabilities & Shareholders' Equity		 11 294 482 732 1,142
Total Liabilities		 6.62 8.79 19 32 72
Total Current Liabilities		 4.38 8.79 19 32 54
Accounts Payable		 1.25 2.89 7.20 9.27 5.23
Accrued Expenses		 1.17 5.89 12 23 49
Total Noncurrent Liabilities		 2.24 0.00 0.00 0.00 18
Other Noncurrent Operating Liabilities		 2.24 - - 0.00 18
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -31 285 463 701 1,070
Total Preferred & Common Equity		 -31 285 463 701 1,070
Preferred Stock		 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -31 285 463 701 1,070
Common Stock		 0.84 363 624 987 1,617
Retained Earnings		 -32 -78 -160 -286 -547
Accumulated Other Comprehensive Income / (Loss)		 0.00 -0.23 -0.49 0.03 -0.06

Quarterly Balance Sheets for Nuvalent

This table presents Nuvalent's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025
Total Assets		 250 461 442 425 708 675 1,189 1,106
Total Current Assets		 245 456 437 420 699 666 1,180 1,087
Cash & Equivalents		 76 90 71 88 99 78 369 121
Short-Term Investments		 164 360 360 325 593 580 799 952
Prepaid Expenses		 5.18 5.83 5.75 6.52 7.66 8.26 11 13
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 4.31 4.70 4.96 5.31 8.97 8.97 9.18 19
Total Liabilities & Shareholders' Equity		 250 461 442 425 708 675 1,189 1,106
Total Liabilities		 13 17 21 29 33 38 68 95
Total Current Liabilities		 13 17 21 29 33 38 51 75
Accounts Payable		 4.62 6.43 8.12 9.78 13 7.40 16 26
Accrued Expenses		 8.36 11 13 19 20 31 35 49
Total Noncurrent Liabilities		 0.00 0.00 0.00 0.00 0.00 0.00 17 20
Other Noncurrent Operating Liabilities		 - - - - - - 17 20
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 237 444 421 396 675 637 1,121 1,011
Total Preferred & Common Equity		 237 444 421 396 675 637 1,121 1,011
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 237 444 421 396 675 637 1,121 1,011
Common Stock		 371 630 637 645 1,007 1,027 1,592 1,642
Retained Earnings		 -134 -185 -214 -248 -331 -388 -472 -632
Accumulated Other Comprehensive Income / (Loss)		 -0.87 -0.30 -1.54 -1.31 -1.32 -1.57 1.37 0.85

Annual Metrics And Ratios for Nuvalent

This table displays calculated financial ratios and metrics derived from Nuvalent's official financial filings.

Metric 2020 2021 2022 2023 2024
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -217.65% -77.84% -65.79% -116.42%
EBIT Growth		 0.00% -219.13% -76.21% -54.20% -122.13%
NOPAT Growth		 0.00% -171.03% -87.94% -73.61% -87.55%
Net Income Growth		 0.00% -218.34% -76.65% -54.20% -106.59%
EPS Growth		 0.00% 58.07% 22.54% -31.52% -81.11%
Operating Cash Flow Growth		 0.00% -167.58% -62.43% -53.51% -85.55%
Free Cash Flow Firm Growth		 0.00% 0.00% -64.76% -75.94% -75.90%
Invested Capital Growth		 0.00% 0.49% -117.75% -84.87% -129.06%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% -11.85% 3.45% -16.92%
EBIT Q/Q Growth		 0.00% 0.00% -10.33% 4.64% -16.57%
NOPAT Q/Q Growth		 0.00% 0.00% -16.07% -12.95% -16.57%
Net Income Q/Q Growth		 0.00% 0.00% -12.10% -10.67% -16.26%
EPS Q/Q Growth		 0.00% 0.00% -166.53% -6.37% -12.93%
Operating Cash Flow Q/Q Growth		 0.00% -25.07% -8.02% -14.24% -20.74%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% -26.54% -13.86%
Invested Capital Q/Q Growth		 0.00% 0.00% -292.21% -11.74% -22.53%
Profitability Metrics		 - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.29%
Interest Burden Percent		 100.00% 99.75% 100.00% 100.00% 92.73%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -361.10% -32.06% -21.89% -21.70% -29.46%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 2,805.95% -28.14% -21.89% -21.70% -29.46%
Return on Equity Simple (ROE_SIMPLE)		 46.47% -16.26% -17.68% -18.02% -24.37%
Net Operating Profit after Tax (NOPAT)		 -12 -32 -60 -105 -196
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -26.35% -9.46% -5.62% -3.59% -6.96%
Return On Investment Capital (ROIC_SIMPLE)		 - - -13.02% -14.94% -18.35%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -15 -46 -82 -126 -280
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -15 -46 -82 -136 -295
Valuation Ratios		 - - - - -
Price to Book Value (P/BV)		 0.00 3.23 3.63 6.58 5.20
Price to Tangible Book Value (P/TBV)		 0.00 3.23 3.63 6.58 5.20
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -2.56 -1.04 -1.03 -1.03 -1.05
Leverage Ratio		 2.64 1.05 1.04 1.04 1.06
Compound Leverage Factor		 2.64 1.05 1.04 1.04 0.98
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 877.05% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -777.05% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 5.72 63.03 51.88 86.92 46.03
Noncontrolling Interest Sharing Ratio		 877.05% 12.23% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - -
Current Ratio		 2.43 33.07 24.54 22.83 20.96
Quick Ratio		 2.36 32.79 24.24 22.62 20.70
Cash Flow Metrics		 - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -32 -53 -93 -164
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - -
Invested Capital		 -6.30 -6.27 -14 -25 -58
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 0.03 -7.38 -12 -33
Enterprise Value (EV)		 176 631 1,209 3,889 4,444
Market Capitalization		 151 919 1,681 4,609 5,562
Book Value per Share		 ($10.92) $5.90 $8.20 $11.19 $15.06
Tangible Book Value per Share		 ($10.92) $5.90 $8.20 $11.19 $15.06
Total Capital		 4.03 285 463 701 1,070
Total Debt		 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00
Net Debt		 -10 -288 -472 -720 -1,118
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -4.07 -6.27 -14 -25 -40
Debt-free Net Working Capital (DFNWC)		 6.27 282 459 695 1,078
Net Working Capital (NWC)		 6.27 282 459 695 1,078
Net Nonoperating Expense (NNE)		 2.72 14 22 22 64
Net Nonoperating Obligations (NNO)		 -10 -291 -477 -726 -1,128
Total Depreciation and Amortization (D&A)		 0.00 0.22 -0.37 -10 -15
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($2.13) ($1.65) ($2.17) ($3.93)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 21.78M 49.67M 58.22M 66.41M
Adjusted Diluted Earnings per Share		 $0.00 ($2.13) ($1.65) ($2.17) ($3.93)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 21.78M 49.67M 58.22M 66.41M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 96.63M 56.70M 64.07M 71.60M
Normalized Net Operating Profit after Tax (NOPAT)		 -12 -32 -60 -105 -196
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -6.52% -0.79% -0.68% -0.19%

Quarterly Metrics And Ratios for Nuvalent

This table displays calculated financial ratios and metrics derived from Nuvalent's official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -64.11% -75.30% -88.08% -99.02% -103.09% -61.05% -70.91% -85.81% -91.37% -87.99% -108.70%
EBIT Growth		 -64.08% -68.36% -70.79% -81.83% -90.22% -58.49% -74.07% -91.27% -96.82% -85.84% -115.00%
NOPAT Growth		 -64.06% -68.60% -70.79% -81.83% -90.22% -58.49% -74.07% -91.27% -96.82% -85.84% -80.29%
Net Income Growth		 -58.67% -51.10% -43.55% -57.53% -70.65% -46.58% -76.57% -96.51% -150.69% -95.24% -90.15%
EPS Growth		 -5.13% -113.77% -22.22% -34.21% -43.90% -26.00% -56.82% -72.55% -116.95% -71.43% -71.01%
Operating Cash Flow Growth		 -59.43% -37.24% -80.28% -43.04% -26.44% -69.91% -47.81% -85.95% -99.37% -105.24% -51.91%
Free Cash Flow Firm Growth		 -63.34% 0.00% -60.89% -23.12% 33.48% -59.37% -61.38% -140.36% -258.62% -33.06% 51.79%
Invested Capital Growth		 -168.18% -117.75% -193.01% -278.03% -548.89% -84.87% -130.29% -98.96% -108.89% -129.06% -215.95%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -9.95% -47.77% -8.68% -12.71% -12.20% -17.18% -15.33% -22.54% -15.56% -15.12% -8.62%
EBIT Q/Q Growth		 -8.83% -43.71% -3.11% -12.75% -13.86% -19.74% -13.25% -23.89% -17.16% -13.06% -9.86%
NOPAT Q/Q Growth		 -8.83% -43.71% -3.11% -12.75% -13.86% -19.74% -13.25% -23.89% -17.16% -13.06% -9.86%
Net Income Q/Q Growth		 -6.77% -32.50% 3.56% -15.47% -15.66% -13.81% -16.17% -28.51% -47.54% 11.36% -13.13%
EPS Q/Q Growth		 -7.89% -21.95% 12.00% -15.91% -15.69% -6.78% -9.52% -27.54% -45.45% 15.63% -9.26%
Operating Cash Flow Q/Q Growth		 -17.45% 2.18% -37.32% 9.33% -3.82% -31.45% -19.46% -14.06% -11.31% -35.32% 11.58%
Free Cash Flow Firm Q/Q Growth		 -16.46% -8.58% -4.95% 7.23% 37.08% -160.15% -6.28% -38.18% 6.13% 3.47% 61.50%
Invested Capital Q/Q Growth		 12.52% -292.21% 18.04% -34.42% -50.17% -11.74% -2.10% -16.14% -57.66% -22.53% -40.83%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.87% 100.30% 100.05% 100.23% 100.19%
Interest Burden Percent		 96.70% 89.16% 83.39% 85.40% 86.75% 82.46% 83.86% 87.48% 110.45% 86.43% 89.04%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -27.16% -21.89% -25.11% -29.70% -36.06% -21.70% -26.01% -32.81% -29.57% -29.46% -35.69%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -27.16% -21.89% -25.11% -29.70% -36.06% -21.70% -26.01% -32.81% -29.57% -29.46% -35.69%
Return on Equity Simple (ROE_SIMPLE)		 -30.86% 0.00% -20.16% -23.77% -28.80% 0.00% -21.56% -27.25% -20.01% 0.00% -29.76%
Net Operating Profit after Tax (NOPAT)		 -14 -21 -21 -24 -27 -33 -37 -46 -53 -60 -66
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -2.01% -1.46% -1.11% -1.51% -1.97% -0.96% -1.33% -2.10% -3.90% -1.55% -2.03%
Return On Investment Capital (ROIC_SIMPLE)		 - -4.43% - - - -4.64% - - - -5.65% -6.56%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -20 -29 -30 -34 -39 -46 -53 -65 -76 -86 -95
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -20 -30 -33 -37 -41 -49 -56 -69 -79 -91 -99
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.98 3.63 3.33 5.69 6.62 6.58 6.97 7.69 5.91 5.20 5.02
Price to Tangible Book Value (P/TBV)		 3.98 3.63 3.33 5.69 6.62 6.58 6.97 7.69 5.91 5.20 5.02
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.01 -1.03 -1.02 -1.03 -1.04 -1.03 -1.03 -1.04 -1.05 -1.05 -1.06
Leverage Ratio		 1.04 1.04 1.04 1.05 1.07 1.04 1.05 1.06 1.06 1.06 1.08
Compound Leverage Factor		 1.00 0.93 0.86 0.89 0.93 0.86 0.88 0.92 1.18 0.92 0.96
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 43.62 52.24 52.52 69.33 54.03 87.28 84.64 76.93 59.09 46.59 32.17
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 18.90 24.54 26.81 21.01 14.42 22.83 20.93 17.45 23.07 20.96 14.48
Quick Ratio		 18.50 24.24 26.47 20.74 14.20 22.62 20.70 17.23 22.85 20.70 14.30
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -12 -13 -14 -13 -8.04 -21 -22 -31 -29 -28 -11
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -3.48 -14 -11 -15 -23 -25 -26 -30 -47 -58 -81
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -2.18 -7.38 -7.37 -11 -19 -12 -15 -15 -25 -33 -56
Enterprise Value (EV)		 701 1,209 1,029 1,965 2,208 3,889 4,011 4,239 5,460 4,444 4,004
Market Capitalization		 941 1,681 1,479 2,396 2,621 4,609 4,703 4,897 6,629 5,562 5,078
Book Value per Share		 $4.89 $8.20 $7.83 $7.41 $6.94 $11.19 $10.52 $9.87 $17.30 $15.06 $14.12
Tangible Book Value per Share		 $4.89 $8.20 $7.83 $7.41 $6.94 $11.19 $10.52 $9.87 $17.30 $15.06 $14.12
Total Capital		 237 463 444 421 396 701 675 637 1,121 1,070 1,011
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -240 -472 -450 -431 -413 -720 -692 -658 -1,168 -1,118 -1,073
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -7.79 -14 -11 -15 -23 -25 -26 -30 -40 -40 -62
Debt-free Net Working Capital (DFNWC)		 232 459 439 416 391 695 666 628 1,129 1,078 1,012
Net Working Capital (NWC)		 232 459 439 416 391 695 666 628 1,129 1,078 1,012
Net Nonoperating Expense (NNE)		 5.44 5.61 4.05 5.25 6.50 5.79 7.67 12 31 14 18
Net Nonoperating Obligations (NNO)		 -240 -477 -455 -436 -419 -726 -701 -667 -1,168 -1,128 -1,092
Total Depreciation and Amortization (D&A)		 -0.00 -0.83 -2.54 -2.85 -2.63 -2.09 -3.38 -3.43 -2.92 -4.93 -4.28
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.41) ($0.50) ($0.44) ($0.51) ($0.59) ($0.63) ($0.69) ($0.88) ($1.28) ($1.08) ($1.18)
Adjusted Weighted Average Basic Shares Outstanding		 48.41M 49.67M 56.70M 56.87M 57.09M 58.22M 64.15M 64.61M 65.68M 66.41M 71.61M
Adjusted Diluted Earnings per Share		 ($0.41) ($0.50) ($0.44) ($0.51) ($0.59) ($0.63) ($0.69) ($0.88) ($1.28) ($1.08) ($1.18)
Adjusted Weighted Average Diluted Shares Outstanding		 48.41M 49.67M 56.70M 56.87M 57.09M 58.22M 64.15M 64.61M 65.68M 66.41M 71.61M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 56.44M 56.70M 56.82M 57.02M 62.63M 64.07M 64.56M 64.80M 71.05M 71.60M 71.81M
Normalized Net Operating Profit after Tax (NOPAT)		 -14 -21 -21 -24 -27 -33 -37 -46 -53 -60 -66
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -0.51% -0.79% -0.82% -0.73% -0.64% -0.68% -0.53% -0.44% -0.43% -0.19% -0.16%

Financials Breakdown Chart

Key Financial Trends

Nuvalent, Inc. (NASDAQ: NUVL) Financial Highlights: Analysis of Last Four Years

Nuvalent operates in the clinical stage with no reported revenue to date, resulting in consistent operating losses as it develops its pipeline. Below are the key financial trends observed from Q3 2022 through Q1 2025:

  • The cash & equivalents balance has largely increased from $76.3M in Q3 2022 to $120.8M in Q1 2025, supported by substantial equity raises.
  • Short-term investments have grown significantly from $164M in Q3 2022 to $952M in Q1 2025, enhancing liquidity and financial flexibility.
  • Total common equity rose considerably from $236.6M in Q3 2022 to $1.01B in Q1 2025, reflecting strong capital infusion from equity issuance.
  • Operating expenses, largely driven by increasing R&D spend, reflect strong investment in drug development: R&D rose from $14.6M in Q3 2022 to $74.4M in Q1 2025.
  • Selling, general & administrative expenses gradually increased from $5.8M (Q3 2022) to $20.4M (Q1 2025), indicating scaling of commercial and administrative infrastructure.
  • Net losses have increased over time as the company expands operations, with net income going from a loss of $19.7M in Q3 2022 to $84.6M loss in Q1 2025.
  • Diluted shares outstanding have grown from about 48.4 million shares in Q3 2022 to approximately 71.6 million in Q1 2025, reflecting ongoing equity financing.
  • Negative operating cash flow persists due to continuous investment in R&D and general expenses, with net cash used in operating activities around -$54.8M in Q1 2025.
  • No revenue generation so far means the company is still in early stages, focusing on development rather than commercialization.
  • Consistent quarterly net losses and negative earnings per share, with Q1 2025 EPS at -$1.18, signal ongoing need for capital and highlight operational risk before product approvals.

Summary: Nuvalent continues to heavily invest in research and development, reflected in growing R&D expenses and increasing operating losses. The company's liquidity position appears solid due to substantial cash and short-term investment balances supported by recent equity financings. However, the absence of revenue and mounting losses emphasize the risks typical of a clinical-stage biopharma, and investors should monitor progress towards clinical milestones and potential commercialization.

10/25/25 05:39 PM ETAI Generated. May Contain Errors.

Frequently Asked Questions About Nuvalent's Financials

When does Nuvalent's fiscal year end?

According to the most recent income statement we have on file, Nuvalent's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Nuvalent's net income changed over the last 4 years?

Nuvalent's net income appears to be on an upward trend, with a most recent value of -$260.76 million in 2024, rising from -$14.56 million in 2020. The previous period was -$126.22 million in 2023. See Nuvalent's forecast for analyst expectations on what’s next for the company.

What is Nuvalent's operating income?
Nuvalent's total operating income in 2024 was -$280.37 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $280.37 million
How has Nuvalent's revenue changed over the last 4 years?

Over the last 4 years, Nuvalent's total revenue changed from $0.00 in 2020 to $0.00 in 2024, a change of 0.0%.

How much debt does Nuvalent have?

Nuvalent's total liabilities were at $71.96 million at the end of 2024, a 126.1% increase from 2023, and a 987.8% increase since 2020.

How much cash does Nuvalent have?

In the past 4 years, Nuvalent's cash and equivalents has ranged from $10.33 million in 2020 to $335.39 million in 2023, and is currently $145.69 million as of their latest financial filing in 2024.

How has Nuvalent's book value per share changed over the last 4 years?

Over the last 4 years, Nuvalent's book value per share changed from -10.92 in 2020 to 15.06 in 2024, a change of -237.8%.


Related Companies

This page (NASDAQ:NUVL) was last updated on 10/25/2025 by MarketBeat.com Staff
From Our Partners
If You Keep Cash In A U.S. Bank Account… Read This NOW
The Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...
Banyan Hill Publishing | Sponsoredtc pixel
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
Traders Agency | Sponsoredtc pixel
$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...
Brownstone Research | Sponsoredtc pixel
Move $1,000 into this stock before Nov 6
The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...
Altimetry | Sponsoredtc pixel
$4,200 gold is nice ... but here’s what most gold bugs are missing
Gold just surged past $4,200, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...
Weiss Ratings | Sponsoredtc pixel
Buy UBER immediately
BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...
Chaikin Analytics | Sponsoredtc pixel
Front-Run Buffett's Shocking Gold Move
A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...
Golden Portfolio | Sponsoredtc pixel
Trump’s new nightmare begins
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...
Porter & Company | Sponsoredtc pixel